Phase 1 study of the safety, tolerability, and pharmacokinetics of the β-lactamase inhibitor vaborbactam (RPX7009) in healthy adult subjects

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 10, 2016, Pages 6326-6332

  Griffith, David C ^a   Loutit, Jeffery S ^a   Morgan, Elizabeth E ^a   Durso, Stephanie ^a   Dudley, Michael N ^a  

^a Medicines Company   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VABORBACTAM; BORONIC ACID DERIVATIVE; SINGLE HETEROCYCLIC RINGS;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTACT DERMATITIS; CONTROLLED STUDY; CREATININE CLEARANCE; DOUBLE BLIND PROCEDURE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; FOLLOW UP; GOOD CLINICAL PRACTICE; HEADACHE; HEMATOMA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; INJECTION SITE THROMBOSIS; LETHARGY; MALE; MAXIMUM PLASMA CONCENTRATION; MYALGIA; NORMAL HUMAN; PHARMACOKINETIC PARAMETERS; PHASE 1 CLINICAL TRIAL; PHLEBITIS; PLASMA CLEARANCE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTEIN BINDING; RANDOMIZED CONTROLLED TRIAL; RENAL CLEARANCE; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; URINARY EXCRETION; URINE SAMPLING; VOLUME OF DISTRIBUTION; CLINICAL TRIAL; HALF LIFE TIME; INTRAVENOUS DRUG ADMINISTRATION;

ADMINISTRATION, INTRAVENOUS; ADULT; BORONIC ACIDS; FEMALE; HALF-LIFE; HEALTHY VOLUNTEERS; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; MALE;

EID: 84992415785     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00568-16     Document Type: Article

References (8)

1. US Department of Health and Human Services Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States, 2013. http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf. Accessed 4 August 2015.
2. Hecker SJ, Reddy KR, Totrov M, Hirst GC, Lomovskaya O, Griffith DC, King P, Tsivkovski R, Sun D, Sabet M, Tarazi Z, Clifton MC, Atkins K, Raymond A, Potts KT, Abendroth J, Boyer SH, Loutit JS, Morgan EE, Durso S, Dudley MN. 2015. Discovery of a cyclic boronic acid β-lactamase inhibitor (RPX7009) with utility vs class A serine carbapenemases. J Med Chem 58:3682-3692. http://dx.doi.org/10.1021/acs.jmedchem.5b00127.
3. Castanheria M, Becker HK, Rhomberg PR, Jones RN. 2014. Effect of the β-lactamase inhibitor RPX7009 combined with meropenem tested against a large collection of KPC-producing Enterobacteriaceae, abstr C-777. Abstr 54th Intersci Conf Antimicrob Agents Chemother. American Society of Microbiology, Washington, DC.
4. Lapuebla A, Abdallah M, Olafisoye O, Cortes C, Urban C, Quale J, Landman D. 2015. Activity of meropenem combined with RPX7009, a novel β-lactamase inhibitor, against Gram-negative clinical isolates in New York City. Antimicrob Agents Chemother 59:4856-4860. http://dx.doi.org/10.1128/AAC.00843-15.
5. Sabet M, Tarazi Z, Nolan T, Parkinson J, Rubio-Aparicio D, Lomovskaya O, Dudley MN, Griffith DC. 2014. In vivo efficacy of Carbavance (meropenem/RPX7009) against KPC-producing Enterobacteriaceae, abstr. F-959. Abstr 54th Intersci Conf Antimicrob Agents Chemother. American Society of Microbiology, Washington, DC.
6. Griffith DC, Sabet M, Tarazi Z, Tsivkovski R, Lomovskaya O, Hecker SJ, Dudley MN. 2012. Nonclinical toxicology and safety profile of the beta-lactamase inhibitor RPX7009, abstr. F-852. Abstr 52nd Intersci Conf Antimicrob Agents Chemother. American Society of Microbiology, Washington, DC.
7. Lomovskaya O, Lomovskaya O, Griffith DC, Loutit JS, Dudley MN. 2015. Rationale for dose selection for Carbavance (CVC; meropenem/RPX7009) in phase 3 trials. Open Forum Infect Dis 2(Suppl 1).
8. Dandekar PK, Maglio D, Sutherland CA, Nightingale CH, Nicolau DP. 2003. Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion. Pharmacotherapy 23:988-991. http://dx.doi.org/10.1592/phco.23.8.988.32878.